BMS RYZ101 (Ac-225 DOTATATE) ACTION-1 hits at interim: the first randomized report card for an alpha radioligand, and how GU should read it

Data as of 2026-10-19 (Taipei time). [Fact] statements are sourced; [Inference] statements are this article's judgment.

1. One-line conclusion

[Fact] ACTION-1 met its BICR PFS primary endpoint at a prespecified interim analysis; the effect size is undisclosed (BMS). [Inference] This shows an alpha radioligand can still extend PFS after beta agents fail. For GU, the real lesson is that a "post-Lu-177" population can support a registrational trial, and the bottleneck will shift from efficacy to Ac-225 supply and nuclear medicine site capacity.

2. What happened

[Fact] On 2026-10-12 US Eastern (the same evening Taipei time), BMS announced that ACTION-1 (NCT05477576) met its primary endpoint at a prespecified interim analysis: RYZ101 produced a statistically significant and clinically meaningful improvement in BICR-assessed PFS versus investigator's choice of standard therapy; safety was consistent with known data (BMS).

• Design: Phase 1b/3, global, randomized, open-label (CT.gov).
• Population: inoperable, SSTR-PET-positive (Krenning 3–4), well-differentiated G1–2 (Ki67 ≤20%) GEP-NET that progressed after 2–4 cycles of Lu-177 SSA, with prior disease control of at least 6 months (CT.gov).
• Comparator: everolimus, sunitinib, or high-dose/high-frequency long-acting SSA (BMS).
• Endpoint: BICR PFS (RECIST 1.1), analyzed at 143 PFS events; actual enrollment 343 (CT.gov). The original plan was 210 patients, randomized 1:1 (RayzeBio release of 2023-05-31; RayzeBio).
• HR, CI, p value, median PFS, event counts: not found; the company says they will be presented at a medical meeting (BMS). OS follow-up continues (BMS).
• [Fact] FDA granted orphan drug designation in August 2026 (BMS). On the day, BMS shares rose 3.5% and then fell 3% an hour later; Fierce attributed this mainly to the same-day pulmonary fibrosis drug news (Fierce).

3. Why it succeeded and why it matters

• Mechanism: [Inference] Ac-225 alpha particles have short range and high linear energy transfer, causing DNA double-strand breaks, and in theory can overcome resistance to beta radiation. Here the same target (SSTR) with a different isotope delivered PFS, supporting a "swap the warhead" strategy.
• Patient selection was key: [Inference] Eligibility required high SSTR-PET expression and at least 6 months of prior response to Lu-177, selecting patients whose "target is still there, but beta was not enough." This is a smart enrichment design, but it means extrapolation to primary-resistant populations does not hold.
• Weak comparator: [Inference] Everolimus, sunitinib or escalated SSA have limited PFS in later-line GEP-NET; with an open-label design, BICR assessment was essential, and BMS used it.
• Statistics: [Inference] Hitting at a prespecified interim suggests a sizable effect, but with 343 patients and 143 events (CT.gov), clinical significance cannot be judged without an HR; the interim alpha spend was also not found.
• Safety: specific figures for renal, bone marrow and salivary gland toxicity: not found.
• Dose and regional distribution: RP3D value and enrollment by region not found.

4. Regulatory and commercial implications

• FDA: [Inference] BICR PFS, randomization and orphan designation make the filing path clear; [Fact] the trial allows SOC patients to cross over to RYZ101 on progression (RayzeBio). [Inference] OS may be diluted as a result, and FDA may still rely mainly on PFS.
• NMPA: China filing plan not found. [Inference] Ac-225 import, radiopharmaceutical controls and hospital nuclear medicine licenses will be practical hurdles.
• Competition: [Inference] There is currently no standard of care after Lu-177; the first to market will define this line.
• For the next trial: [Inference] sponsors planning GU radioligand trials can cite ACTION-1's design (post-Lu-177, BICR PFS, prespecified interim analysis) as precedent in FDA discussions.
• GU relevance (mostly inference): Prostate cancer is the largest potential market for Ac-225, and several Ac-225 PSMA programs are in development; ACTION-1 provides an analogy for the feasibility of a "post-Lu-PSMA" design. Names and status of Ac-225 PSMA trials in GU were not verified here; recorded as not found.

5. Lessons for the next trial design and OncoLattice recommendations

All recommendations below are [Inference]; cited facts carry their own sources.

1. Replicate the "post-beta, target still present" enrichment. A GU version could read: progression after Lu-PSMA, persistently high PSMA-PET expression, and prior response of a defined duration.
2. Use BICR rPFS as the primary endpoint, with a prespecified interim analysis. ACTION-1 shows an open-label RLT trial with BICR can convince the market.
3. Build isotope supply into feasibility. [Inference] Ac-225 capacity is limited; confirm each site's dose scheduling, shipping window and backup source before site selection, or supply will throttle enrollment.
4. Nuclear medicine capability is the first site-selection gate. Sites need SSTR/PSMA-PET, radiopharmaceutical handling and waste licenses, dosimetry, and a urology–nuclear medicine referral pathway. Urology-led sites that outsource nuclear medicine carry high execution risk.
5. Prespecify long-term toxicity follow-up: [Fact] delayed nephrotoxicity (tubulointerstitial nephritis, progressive CKD) has been reported in case reports after Ac-225-PSMA therapy (Clin Nucl Med, case report); the largest Ac-225-PSMA retrospective study, WARMTH Act, had a median follow-up of only 9.0 months (Lancet Oncol). These are PSMA-ligand data, not RYZ101. [Inference] Long-term renal data for alpha agents are thin, so the protocol should define multi-year follow-up upfront.

6. Unknowns and what to watch

• HR, CI, median PFS, OS trend and crossover rate at the medical meeting.
• Grade ≥3 adverse events, renal function and bone marrow toxicity.
• Whether commercial Ac-225 supply can support launch.
• Whether "first successful alpha RLT Phase 3" is accurate.

Evidence limitations

Only a company topline press release is available, with no effect size; the trial is open-label, and the investigator-chosen control arm is heterogeneous. The GU section is inference by analogy, not ACTION-1 data.

Endnote: differences from the original forwarded account

(1) "first successful alpha radioligand Phase 3" does not appear in Fierce or the BMS release, and this article did not verify it independently; it should be labeled an unverified claim. (2) The population progressed after "Lu-177-class therapy," not only Lutathera (BMS, CT.gov).